Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 2, 1998, Pages 293-297

  Noormohamed, Faruq H ^a   Youle, Michael S ^b   Higgs, Christopher J ^b   Martin Munley, Sarah ^c   Gazzard, Brian G ^b   Lant, Ariel F ^a,b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c Astra USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET;

ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; FOSCARNET; HIV; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; XYLOSE;

EID: 0031952853     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Anderson, R. D., K. G. Griffy, D. Jung, A. Dorr, J. D. Hulse, and R. B. Smith. 1995. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000 mg/d dosing regimens in human immunodeficiency virus-seropositive patients. Clin. Ther 17:425-432.
2. Aweeka, F., J. Gambertoglio, J. Mills, and M. A. Jacobson. 1989. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodenciency syndrome patients with serious cytomegalovirus retinitis. Antimicrob. Agents Chemother. 33:742-745.
3. Barditch-Crovo, P., B. G. Petty, J. Gambertoglio, L. J. Nerhood, S. Kuwahara, R. Hafner, P. S. Lietman, and D. M. Kornhauser. 1991. The effect of increasing gastric pH upon bioavailability of orally administered phosphonoformic acid (foscarnet), abstr. WB 2115. In Abstracts of the 7th International Conference on AIDS.
4. Bonsnes, R. W., and H. H. Taussky. 1945. The colorimetric determination of creatinine by the Jaffe reaction. J. Biol. Chem. 158:581-591.
5. Brøchner-Mortensen, J. 1985. Current status on assessment and measurement of glomerular filtration rate. Clin. Physiol. 5:1-17.
6. Chrisp, P., and S. P. Clissold. 1991. Foscarnet. Drugs 41:104-129.
7. Cundy, K. C., B. G. Petty, J. Flaherty, P. E. Fisher, M. A. Polis, M. Wachsman, P. S. Lietman, J. P. Lalezari, M. J. M. Hitchcock, and H. S. Jaffe. 1995. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 39:1247-1252.
8. Dixey, J. J., F. H. Noormohamed, J. S. Pawa, A. F. Lant, and D. A. Brewerton. 1988. The influence of nonsteroidal anti-inflammatory drugs and pro-benecid on the renal response to and kinetics of piretanide in man. Clin. Pharmacol. Ther. 44:531-539.
9. 51Cr EDTA acid, inulin and endogenous creatinine clearances in 20 patients with renal disease. Br. Med. J. 1:84-86.
10. Haeney, M. R., L. S. Culank, R. D. Montgomery, and H. G. Sammons. 1978. Evaluation of xylose absorption as measured in blood and urine: a one-hour blood xylose screening test in malabsorptin. Gastroenterology 75:393-400.
11. Jacobson, M. A., P. de-Miranda, D. M. Cederberg, T. Burnette, E. Cobb, H. R. Brodie, and J. Mills. 1987. Human pharmacokinetics of and tolerance of oral ganciclovir. Antimicrob. Agents Chemother. 31:1251-1254.
12. Katlama, C., E., Dohin, E. Caumes, I. Cochereau-Massin, C. Brancon, M. Robinet, O. Rogeaux, R. Dahan, and M. Gentilini. 1992. Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimes. J. Acquired Immune Defic. Syndr. 5(Suppl. 1): S18-S24.
13. Midha, K. K., E. D. Ormsby, J. W. Hubbard, G. McKay, E. M. Hawes, I. Gavalas, and I. J. McGilveray. 1993. Logarithmic transformation in bio-equivalence: application with two formulations of perphenazine. J. Pharm. Sci. 82:138-144.
14. Noormohamed, F. H., M. S. Youle, C. J. Higgs, B. G. Gazzard, and A. F. Lant. 1997. Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment. Br. J. Clin. Pharmacol. 43:112-115.
15. 14a. Noormohamed, F. H., M. S. Youle, C. J. Higgs, S. Martin-Munley, B. G. Gazzard, and A. F. Lant. 1994. Pharmacokinetics and bioavailability of oral foscarnet in HIV seropositive patients. J. Clin. Pharmacol. 34:1013.
16. Noormohamed, F. H., M. S. Youle, B. Tang, S. Martin-Munley, B. G. Gazzard, and A. F. Lant. 1996. Foscarnet-induced changes in plasma concentrations of total and ionised calcium and magnesium in HIV-positive patients. Antivir. Ther. 1:172-179.
17. Oberg, B. 1983. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol. Ther. 19:387-415.
18. Palestine, A. G., M. A. Polis, M. D. De Smet, B. F. Baird, J. Falloon, J. A. Kovacs, R. T. Davey, J. J. Zurlo, K. M. Zunich, M. Davis, L. Hubbard, R. Brothers, F. L. Ferris, E. Chew, J. L. Davis, B. I. Rubin, S. D. Mellow, J. A. Metcalf, J. Manischewitz, J. R. Minor, R. B. Nussenblatt, H. Masur, and H. C. Lane. 1991. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. J. Intern. Med. 115:665-673.
19. Petterson, K. J., T. Nordgren, and D. Westerlund. 1989. Determination of phosphonoformate (foscarnet) in biological fluids by ion-paired, reversed-phase liquid chromatography. J. Chromatogr. 488:447-455.
20. Polis, M. A., M. D. De Smet, B. F. Baird, S. D. Mellow, J. Fallon, R. T. Davey, J. A. Kovacs, A. G. Palestine, R. B. Nussenblatt, H. Masur, and H. C. Lane. 1993. Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). Am. J. Med. 94:175-180.
21. Polis, M. A., K. M. Spooner, B. F. Baird, J. F. Manischewitz, H. S. Jaffe, P. E. Fisher, J. Falloon, R. T. Davey, Jr., J. A. Kovacs, R. E. Walker, S. M. Whitcup, R. B. Nussenblatt, H. C. Lane, and H. Masur. 1996. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob. Agents. Chemother. 39:882-886.
22. Sjovall, J., S. Bergdahl, G. Movin, S. Ogenstad, and M. Saarimaki. 1989. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 33:1023-1031.
23. Sjovall, J., A. Karlson, S. Ogenstad, E. Sandstrom, and M. Saarimaki. 1988. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin. Pharmacol. Ther. 44:65-73.
24. Spector, S. A., B. F. Busch, S. Follansbee, K. Squires, J. P. Lalezari, M. A. Jacobson, J. D. Connor, D. Jung, A. Shadman, B. Mastre, W. Buhles, W. L. Drew, AIDS Clinical Trial Group, and Cytomegalovirus Cooperative Study Group. 1995. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J. Infect. Dis. 171:1431-1437.
25. Spector, S. A., G. F. McKinley, J. P. Lalezari, T. Samo, R. Andruczk, S. Follansbee, P.D. Sparti, D. V. Havlir, G. Simpson, W. Buhles, R. Wong, and M. J. Stempien for the Roche Cooperative Oral Ganciclovir Study Group. 1996. Oral ganciclovir for the prevention of cytomegalovirus disease in persons AIDS. N. Engl. J. Med. 334:1491-1497.
26. Taburet, A.-M., C. Katlama, C. Blanshard, G. Gorza, D. Gazzard, E. Dohin, B. G. Gazzard, C. Frostegard, and E. Singlas. 1992. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 36:1821-1824.